Floria, M.; Oancea, A.F.; Morariu, P.C.; Burlacu, A.; Iov, D.E.; Chiriac, C.P.; Baroi, G.L.; Stafie, C.S.; Cuciureanu, M.; Scripcariu, V.; Tanase, D.M. An Overview of the Pharmacokinetics and Pharmacodynamics of Landiolol (an Ultra-Short Acting β1 Selective Antagonist) in Atrial Fibrillation. Pharmaceutics2024, 16, 517.
Floria, M.; Oancea, A.F.; Morariu, P.C.; Burlacu, A.; Iov, D.E.; Chiriac, C.P.; Baroi, G.L.; Stafie, C.S.; Cuciureanu, M.; Scripcariu, V.; Tanase, D.M. An Overview of the Pharmacokinetics and Pharmacodynamics of Landiolol (an Ultra-Short Acting β1 Selective Antagonist) in Atrial Fibrillation. Pharmaceutics 2024, 16, 517.
Floria, M.; Oancea, A.F.; Morariu, P.C.; Burlacu, A.; Iov, D.E.; Chiriac, C.P.; Baroi, G.L.; Stafie, C.S.; Cuciureanu, M.; Scripcariu, V.; Tanase, D.M. An Overview of the Pharmacokinetics and Pharmacodynamics of Landiolol (an Ultra-Short Acting β1 Selective Antagonist) in Atrial Fibrillation. Pharmaceutics2024, 16, 517.
Floria, M.; Oancea, A.F.; Morariu, P.C.; Burlacu, A.; Iov, D.E.; Chiriac, C.P.; Baroi, G.L.; Stafie, C.S.; Cuciureanu, M.; Scripcariu, V.; Tanase, D.M. An Overview of the Pharmacokinetics and Pharmacodynamics of Landiolol (an Ultra-Short Acting β1 Selective Antagonist) in Atrial Fibrillation. Pharmaceutics 2024, 16, 517.
Abstract
Landiolol is an ultra-short-acting, selective ß1- adrenergic receptor blocker that was originally approved by Japan for the treatment of intraoperative tachyarrhythmias. It has gained attention for its use in the management of tachyarrhythmias and perioperative tachycardia, especially atrial fibrillation for both cardiac and non-cardiac surgeries. It can be the ideal agent for heart rate control due to its high β1‐selectivity, the potent negative chronotropic effect, a limited negative inotropic potential, and an ultrashort elimination half‐life (around 4 min); moreover, it may have a potential therapeutic effect for sepsis and pediatric patients. Landiolol seems to be superior to other short‐acting and selective beta‐blockers such as esmolol. This review aims to provide a comprehensive overview of landiolol, a new ultra-short-acting ß1 selective antagonist, including its pharmacology, clinical applications, efficacy, safety profile, and future directions in research and clinical data.
Medicine and Pharmacology, Cardiac and Cardiovascular Systems
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
